Lexeo Therapeutics, Inc.
US ˙ NasdaqGM ˙ US52886X1072

SecurityLXEO / Lexeo Therapeutics, Inc.
InstitutionCaxton Corp
Latest Disclosed Ownership13,943 shares
Latest Disclosed Value $ 80,032
Caxton Corp ownership in LXEO / Lexeo Therapeutics, Inc.

On May 14, 2026 - Caxton Corp filed a 13F-HR form disclosing ownership of 13,943 shares of Lexeo Therapeutics, Inc. (US:LXEO) valued at $80,033 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 13,943 shares of Lexeo Therapeutics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $66,648 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F LEXEO THERAPEUTICS COM 52886X107 13,943 0 0.00 80 -42.03 1.9887
2026-02-13 2025-12-31 13F LEXEO THERAPEUTICS COM 52886X107 13,943 -3,389 -19.55 138 20.00 3.2355
2025-11-14 2025-09-30 13F LEXEO THERAPEUTICS COM 52886X107 17,332 0 0.00 115 66.67 0.5034
2025-08-14 2025-06-30 13F LEXEO THERAPEUTICS COM 52886X107 17,332 -519 -2.91 70 13.11 0.7071
2025-05-15 2025-03-31 13F LEXEO THERAPEUTICS COM 52886X107 17,851 0 0.00 62 -47.86 1.2192
2025-02-14 2024-12-31 13F LEXEO THERAPEUTICS COM 52886X107 17,851 0 0.00 117 -27.33 0.7060
2024-11-14 2024-09-30 13F LEXEO THERAPEUTICS COM 52886X107 17,851 0 0.00 161 -43.71 0.6679
2024-08-14 2024-06-30 13F LEXEO THERAPEUTICS COM 52886X107 17,851 7,532 72.99 286 77.64 1.4512
2024-05-15 2024-03-31 13F LEXEO THERAPEUTICS COM 52886X107 10,319 0 0.00 162 16.67 0.9218
2024-02-14 2023-12-31 13F LEXEO THERAPEUTICS COM 52886X107 10,319 10,319 138 0.7475
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.